Team Members

Ozgur Sahin, PhD

MANAGER

Ozgur Sahin, PhD

Dr. Sahin is an experienced cancer biologist with a strong background in functional genomics, bioinformatics, and drug discovery. He discovered the roles of many proteins and non-coding RNAs in the pathogenesis of drug resistant and metastatic cancers. Dr. Sahin is currently a Professor and Endowed Chair in the Department of Biochemistry & Molecular Biology and the Co-leader of the Breast Transdisciplinary Cancer Team (TcT) at Hollings Cancer Center at Medical University of South Carolina (MUSC), Charleston, SC. Previously, he served as Research Team Leader at German Cancer Research Center (DKFZ), Research Faculty in the Department of Molecular & Cellular Oncology at the University of Texas MD Anderson Cancer Center (MDACC), Assistant Professor in the Department of Molecular Biology & Genetics at Bilkent University and Associate Professor in the Department of Drug Discovery & Biomedical Sciences at the University of South Carolina. To date, Dr. Sahin published more than 70 peer-reviewed papers in the field of cancer research in high impact international journals and filed multiple patent applications. He is also the founder and president of LoxiGen, Inc. developing novel LOX inhibitors.

Erden Banoglu, PhD

MEMBER

Erden Banoglu, PhD

Prof. Banoglu is a Medicinal Chemist with over 25 years of drug discovery experience. He is a graduate of Pharmacy with a PhD degree in Medicinal and Natural Products Chemistry from the University of Iowa (USA) in 1997. He also worked in Aberdeen University (Scotland) as a British Council Scholar, in Kumamoto University (Japan) as a JICA scholar and did postdoctoral study in the Department of Biomedical Sciences at the University of Rhode Island (USA). He currently is the Department Head in the Department of Pharmaceutical Chemistry at Gazi University (Ankara, Turkey). Currently, his research group is involved in the discovery and development of new molecules for pathologies associated with cancer development and inflammation, especially targeting 5-lipoxygenase-activating protein (FLAP), and microsomal prostaglandin E2 synthase-1 (mPGES-1), which are important targets for treatment of chronic inflammatory and cardiovascular diseases and cancer. He is co-funder and deputy chief executive of Icosyn Therapeutics and also the Principal Member of the Turkish Academy of Sciences (TUBA).

Burcu Caliskan, PhD

MEMBER

Burcu Caliskan, PhD

Prof. Caliskan is an experienced Medicinal Chemist with strong background in synthetic organic chemistry and drug development. After her graduation from the School of Pharmacy, she obtained her master’s and PhD degrees in the Department of Pharmaceutical Chemistry at Gazi University (Ankara, Turkey). She also worked as a Medicinal Chemist in the Department of Medicinal Chemistry at University of Perugia (Italy). She is involved in the design, discovery and synthetic development of novel scaffolds as novel drug candidated towards inflammation and cancer, especially targeting 5-lipoxygenase-activating protein (FLAP), and microsomal prostaglandin E2 synthase-1 (mPGES-1). She is also co-funder of Icosyn Therapeutics developing mPGES-1 inhibitors against chronic inflammation in a wide range of diseases.

OncoCube Therapeutics is driven by a passionate and expert team of researchers, scientists, and professionals. With deep knowledge and experience in cancer research, our team is dedicated to making a difference in the field of cancer treatment. Together, we strive to develop unique and effective therapies such as TACC3 inhibitors. OncoCube family is committed to improving the lives of cancer patients and making a significant impact in global healthcare.

Subscribe

Follow us to stay updated on the latest advancements in innovative cancer therapies and OncoCube's progress. Get firsthand access to important information for your health!

Subscription Form